Avadel Pharma (AVDL) Tops Q1 EPS by 1c ; Offers Guidance

Avadel Pharma (NASDAQ: AVDL) reported Q1 EPS of ($0.05), $0.01 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $52.5 million versus the consensus estimate of $53.25 million.

GUIDANCE:

Avadel Pharma sees FY2025 revenue of $255-265 million, versus the consensus of $249.2 million.

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.

You May Also Be Interested In

• JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
• JPMorgan Starts Multi Commodity Exchange of India Ltd (MCX:IN) at Underweight
• JPMorgan Starts Nippon Life India Asset Management Ltd (NAM:IN) at Overweight